Wellington Management Co. LLP recently announced the acquisition of new stake in Amneal Pharmaceuticals Inc. (NYSE:AMRX). The institutional investor has increased its shareholding in the Healthcare company by 0.10% to 15.34 million shares with purchase of 15607.0 shares. This fresh investment now brings its stake to 10.41% valued currently at $66.42 million. In addition, The Vanguard Group, Inc. raised its holdings by 0.51 million to 10.87 million shares. And SSgA Funds Management, Inc. has lifted its position by 14.84% or 0.36 million shares – to 2.78 million shares.
With over 1.08 million Amneal Pharmaceuticals Inc. (AMRX) shares trading Monday and a closing price of $4.11 on the day, the dollar volume was approximately $4.44 million. The shares have shown a positive weekly performance of 3.27% and its price on 08/31/20 gained nearly 1.99%. Currently, there are 147.39M common shares owned by the public and among those 115.92M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 11 analysts who have offered their price forecasts for AMRX have a consensus price objective of $4.56. The analysts have set the share’s price value over the next 12 months at a high of $6.00 and a low of $3.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Amneal Pharmaceuticals Inc. stock is 3.00 for the next 12 months. The average price target is 3.29% above its last price level and an upside to the estimated low will see the stock lose -37.0% over that period. But an upside of 31.5% will see the stock hit the forecast high price target while mean target price for the stock is $4.75.
Insiders at the company have transacted a total of 40 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 32 of these insider trades were purchases, accounting for 1,486,952 shares. Insider sales of the common stock occurred on 8 occasions, with total insider shares sold totaling 44,463 shares.
The top 3 mutual fund holders in Amneal Pharmaceuticals Inc. are Vanguard Health Care Fund, Vanguard Total Stock Market Index, and Vanguard Small Cap Index Fund. Vanguard Health Care Fund owns 9.31 million shares of the company’s stock, all valued at over $40.3 million. Vanguard Small Cap Index Fund sold 17360.0 shares to bring its total holdings to over 2.94 million shares at a value of $12.72 million. Vanguard Small Cap Index Fund now owns shares totaling to 1.99% of the shares outstanding.
Shares of Amneal Pharmaceuticals Inc. (NYSE: AMRX) opened at $4.01, down -$0.02 from a prior closing price of $4.03. However, the script later closed the day at $4.11, up 1.99%. The company’s stock has a 5-day price change of 3.27% and -12.55% over the past three months. AMRX shares are trading -14.73% year to date (YTD), with the 12-month market performance up to 61.18% higher. It has a 12-month low price of $2.36 and touched a high of $5.79 over the same period. Currently, 1.08 million shares have been traded, compared to an average intraday trading volume of 1.35 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.09%, -8.83%, and -1.92% respectively.
Institutional ownership of Amneal Pharmaceuticals Inc. (NYSE: AMRX) shares accounts for 70.00% of the company’s 147.39M shares outstanding. Mutual fund holders own 25.72%, while other institutional holders and individual stakeholders account for 38.52% and 17.92% respectively.
It has a market capitalization of $1.26B and a beta (3y monthly) value of 1.38. The earnings-per-share (ttm) stands at -$1.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.26% over the week and 5.81% over the month.
Analysts forecast that Amneal Pharmaceuticals Inc. (AMRX) will achieve an EPS of $0.11 for the current quarter, $0.14 for the next quarter and $0.69 for 2021. The lowest estimate earnings-per-share for the quarter is $0.08 while analysts give the company a high EPS estimate of $0.14. Comparatively, EPS for the current quarter was $0.04 a year ago. Earnings per share for the fiscal year are expected to increase by 65.70%, and 18.15% over the next financial year. EPS should grow at an annualized rate of -12.10% over the next five years, compared to -40.00% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 11 brokerage firm advisors rate Amneal Pharmaceuticals Inc. (AMRX) as a “Hold” at a consensus score of 3.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 7 of the 11 advise that investors “hold,” and 2 rated it as a “Sell.”
Looking at the support for the AMRX, a number of firms have released research notes about the stock. Goldman stated their Sell rating for the stock in a research note on July 27, 2020, with the firm’s price target at $4. Guggenheim coverage for the Amneal Pharmaceuticals Inc. (AMRX) stock in a research note released on May 12, 2020 offered a Neutral rating with a price target of. Raymond James was of a view on December 12, 2019 that the stock is Mkt Perform, while JP Morgan gave the stock Underweight rating on November 12, 2019, issuing a price target of. SVB Leerink on their part issued Mkt Perform rating on November 07, 2019.